AtG Therapeutics Appoints Dr. Itziar Canamasas as New CEO to Drive Development of Cancer Metabolic Adaptation Inhibitors

AtG Therapeutics, a pre-clinical stage biotech focused on stopping cancer metabolic adaptation, has announced the appointment of Itziar Canamasas, PhD as its new CEO.

Dr. Canamasas brings over 20 years of experience in the pharmaceutical industry, with expertise focused on global commercialisation, strategic life-cycle development, corporate strategy, and country leadership. She was most recently the Head of Oncology EMEA at Bayer Pharmaceuticals.

Dr. Canamasas will lead the company’s efforts to develop a pipeline of metabolic adaptation inhibitors and biomarkers to treat advanced cancer patients.